Biosion
Dr. Yeh brings to Biosion over 15 years of experience in healthcare, investment, and management consulting. Dr. Yeh joined Biosion from CStone Pharmaceuticals (HKSE: 2616), where he served as Vice President, Head of Corporate Strategy, Capital Market and Investor Relations. During his tenure at CStone Pharmaceuticals, Dr. Yeh served several different leadership roles in helping to build CStone through public listing and eventually to commercialization stage. Prior to CStone, Dr. Yeh was Regional Head of Business Economics and Strategy at Abbott (NYSE: ABT) and engagement manager at L.E.K. Consulting where he specialized in life sciences strategy and M&A.
Dr. Yeh holds a Ph.D. in Molecular Medicine from University of Oxford and a Bachelor of Science (honors) from Queensland University of Technology.
This person is not in any offices
Biosion
Biosion is a leading “In Global For Global” clinical stage biotechnology company developing innovative biologics to address resistant, relapsed and residual disease for patients worldwide.